Aktuelle Aspekte der intensivmedizinischen Versorgung bei Schädel-Hirn-Trauma – Teil 2

Das Schädel-Hirn-Trauma ist ein komplexes Krankheitsbild mit hoher Mortalität. In Teil 1 dieses Beitrags wurden primäre Behandlungsstrategien, hämodynamisches Management und multimodales Monitoring behandelt [1], Teil 2 fokussiert nun sekundäre Behandlungsstrategien, Langzeitergebnis, Neuroprognostik und Chronifizierung.

Abstract

This two-part article deals with the intensive medical care of traumatic brain injury. Part 1 addresses the primary treatment strategy, haemodynamic management and multimodal monitoring, Part 2 secondary treatment strategies, long-term outcome, neuroprognostics and chronification. Traumatic brain injury is a complex clinical entity with a high mortality rate. The primary aim is to maintain homeostasis based on physiological targeted values. In addition, further therapy must be geared towards intracranial pressure. In addition to this, there are other monitoring options that appear sensible from a pathophysiological point of view with appropriate therapy adjustment. However, there is still a lack of data on their effectiveness. A further aspect is the inflammation of the cerebrum with the “cross-talk” of the organs, which has a significant influence on further intensive medical care.

Schlüsselwörter

Schädel-Hirn-Trauma - sekundäre Behandlungsstrategie - Hämodynamik - multimodales Monitoring - Beatmung - Ernährung - Frührehabilitation

Keywords

traumatic brain injury - secondary treatment strategy - haemodynamic management - multimodal monitoring - ventilation - nutrition - early rehabilitation

• Literatur

• 1 Haberl A, Adamzik M, Hagedorn A. et al. Aktuelle Aspekte der intensivmedizinischen Versorgung bei Schädel-Hirn-Trauma – Teil 1: Primäre Therapiestrategien, hämodynamisches Management und multimodales Monitoring. Anasthesiol Intensivmed Notfallmed Schmerzther 2024; 59: 450-465
• 2 Carney N, Totten AM, O’Reilly C. et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery 2017; 80: 6-15
• 3 Gouvea Bogossian E, Cantos J, Farinella A. et al. The effect of increased positive end expiratory pressure on brain tissue oxygenation and intracranial pressure in acute brain injury patients. Sci Rep 2023; 13: 16657
• 4 Robba C, Rebora P, Banzato E. et al. Incidence, Risk Factors, and Effects on Outcome of Ventilator-Associated Pneumonia in Patients With Traumatic Brain Injury: Analysis of a Large, Multicenter, Prospective, Observational Longitudinal Study. Chest 2020; 158: 2292-2303
• 5 Robba C, Poole D, McNett M. et al. Mechanical ventilation in patients with acute brain injury: recommendations of the European Society of Intensive Care Medicine consensus. Intensive Care Med 2020; 46: 2397-2410
• 6 CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019; 394: 1713-1723
• 7 Dauwe DF, Gunst J, Vlasselaers D. et al. Propofol-infusion syndrome in traumatic brain injury: consider the ECMO option. Intensive Care Med 2021; 47: 127-129
• 8 Unterberg M, Nowak H, Gottschalk A. [Hypercapnic Raised Intracerebral Pressure – Ecmo Therapy Despite Major Intracerebral Haemorrhage]. Anasthesiol Intensivmed Notfallmed Schmerzther 2017; 52: 376-381
• 9 McDonald SJ, Sharkey JM, Sun M. et al. Beyond the Brain: Peripheral Interactions after Traumatic Brain Injury. J Neurotrauma 2020; 37: 770-781
• 10 De Vlieger G, Meyfroidt G. Kidney Dysfunction After Traumatic Brain Injury: Pathophysiology and General Management. Neurocrit Care 2023; 38: 504-516
• 11 Perkins ZB, Haines RW, Prowle JR. Trauma-associated acute kidney injury. Curr Opin Crit Care 2019; 25: 565-572
• 12 Semler MW, Self WH, Wanderer JP. et al. Balanced Crystalloids versus Saline in Critically Ill Adults. N Engl J Med 2018; 378: 829-839
• 13 Young P, Bailey M, Beasley R. et al. Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit: The SPLIT Randomized Clinical Trial. JAMA 2015; 314: 1701-1710
• 14 SAFE Stud Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group, Australian Red Cross Blood Servive. et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007; 357: 874-884
• 15 Cerda-Esteve M, Cuadrado-Godia E, Chillaron JJ. et al. Cerebral salt wasting syndrome: review. Eur J Intern Med 2008; 19: 249-254
• 16 Leonard J, Garrett RE, Salottolo K. et al. Cerebral salt wasting after traumatic brain injury: a review of the literature. Scand J Trauma Resusc Emerg Med 2015; 23: 98
• 17 Dijkink S, Meier K, Krijnen P. et al. Malnutrition and its effects in severely injured trauma patients. Eur J Trauma Emerg Surg 2020; 46: 993-1004
• 18 Hartl R, Gerber LM, Ni Q. et al. Effect of early nutrition on deaths due to severe traumatic brain injury. J Neurosurg 2008; 109: 50-56
• 19 Martin CM, Doig GS, Heyland DK. et al. Multicentre, cluster-randomized clinical trial of algorithms for critical-care enteral and parenteral therapy (ACCEPT). CMAJ 2004; 170: 197-204
• 20 Elke G, van Zanten AR, Lemieux M. et al. Enteral versus parenteral nutrition in critically ill patients: an updated systematic review and meta-analysis of randomized controlled trials. Crit Care 2016; 20: 117
• 21 Zusman O, Kagan I, Bendavid I. et al. Predictive equations versus measured energy expenditure by indirect calorimetry: A retrospective validation. Clin Nutr 2019; 38: 1206-1210
• 22 Singer P, Blaser AR, Berger MM. et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr 2019; 38: 48-79
• 23 Mehanna HM, Moledina J, Travis J. Refeeding syndrome: what it is, and how to prevent and treat it. BMJ 2008; 336: 1495-1498
• 24 Nazwar TA, Triangto I, Pringga GA. et al. Mobilization phases in traumatic brain injury. Acute Crit Care 2023; 38: 261-270
• 25 Akira M, Yuichi T, Tomotaka U. et al. The Outcome of Neurorehabilitation Efficacy and Management of Traumatic Brain Injury. Front Hum Neurosci 2022; 16: 870190
• 26 Kadry H, Noorani B, Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS 2020; 17: 69
• 27 Linnerbauer M, Wheeler MA, Quintana FJ. Astrocyte Crosstalk in CNS Inflammation. Neuron 2020; 108: 608-622
• 28 Takeda H, Yamaguchi T, Yano H. et al. Microglial metabolic disturbances and neuroinflammation in cerebral infarction. J Pharmacol Sci 2021; 145: 130-139
• 29 Nott A, Glass CK. Immune memory in the brain. Nature 2018; 556: 312-313
• 30 Dawson VL, Dawson TM. Nitric oxide neurotoxicity. J Chem Neuroanat 1996; 10: 179-190
• 31 Goshi N, Morgan RK, Lein PJ. et al. A primary neural cell culture model to study neuron, astrocyte, and microglia interactions in neuroinflammation. J Neuroinflammation 2020; 17: 155
• 32 Campolo M, Casili G, Lanza M. et al. The inhibition of mammalian target of rapamycin (mTOR) in improving inflammatory response after traumatic brain injury. J Cell Mol Med 2021; 25: 7855-7866
• 33 Ismael S, Ahmed HA, Adris T. et al. The NLRP3 inflammasome: a potential therapeutic target for traumatic brain injury. Neural Regen Res 2021; 16: 49-57
• 34 Geeraerts T, Haik W, Tremey B. et al. [Coagulation disorders after traumatic brain injury: pathophysiology and therapeutic implications]. Ann Fr Anesth Reanim 2010; 29: e177-e181
• 35 Epstein DS, Mitra B, O’Reilly G. et al. Acute traumatic coagulopathy in the setting of isolated traumatic brain injury: a systematic review and meta-analysis. Injury 2014; 45: 819-824
• 36 Gando S, Sawamura A, Hayakawa M. Trauma, shock, and disseminated intravascular coagulation: lessons from the classical literature. Ann Surg 2011; 254: 10-19
• 37 Taylor Jr FB, Toh CH, Hoots WK. et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-1330
• 38 Wada T, Shiraishi A, Gando S. et al. Pathophysiology of Coagulopathy Induced by Traumatic Brain Injury Is Identical to That of Disseminated Intravascular Coagulation With Hyperfibrinolysis. Front Med (Lausanne) 2021; 8: 767637
• 39 Lawati KA, Sharif S, Maqbali SA. et al. Efficacy and safety of tranexamic acid in acute traumatic brain injury: a systematic review and meta-analysis of randomized-controlled trials. Intensive Care Med 2021; 47: 14-27
• 40 Vestal ML, Hodulik K, Mando-Vandrick J. et al. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. J Thromb Thrombolysis 2022; 53: 167-175
• 41 Connolly SJ, Sharma M, Cohen AT. et al. Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. N Engl J Med 2024; 390: 1745-1755
• 42 Kornblith LZ, Moore HB, Cohen MJ. Trauma-induced coagulopathy: The past, present, and future. J Thromb Haemost 2019; 17: 852-862
• 43 Ng IC, Barnes C, Biswas S. et al. When is it safe to resume anticoagulation in traumatic brain injury?. Curr Opin Anaesthesiol 2022; 35: 166-171
• 44 Maas AI, Steyerberg EW, Butcher I. et al. Prognostic value of computerized tomography scan characteristics in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007; 24: 303-314
• 45 McCrea MA, Giacino JT, Barber J. et al. Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study. JAMA Neurol 2021; 78: 982-992
• 46 Wilkins TE, Beers SR, Borrasso AJ. et al. Favorable Functional Recovery in Severe Traumatic Brain Injury Survivors beyond Six Months. J Neurotrauma 2019; 36: 3158-3163
• 47 Wiles MD. Management of traumatic brain injury: a narrative review of current evidence. Anaesthesia 2022; 77 (Suppl. 1) 102-112
• 48 Katar S, Aydin Ozturk P, Ozel M. et al. The Use of Rotterdam CT Score for Prediction of Outcomes in Pediatric Traumatic Brain Injury Patients Admitted to Emergency Service. Pediatr Neurosurg 2020; 55: 237-243
• 49 Kühnle E, Unterberg M, Köditz R. et al. Ein erstaunlich guter Verlauf bei einer Patientin nach kardiopulmonaler Reanimation trotz Burst-Suppression-Muster und NSE-Werten über 100 μg/l. Neurol Rehabil 2017; 23: 99-102
• 50 Edalatfar M, Piri SM, Mehrabinejad MM. et al. Biofluid Biomarkers in Traumatic Brain Injury: A Systematic Scoping Review. Neurocrit Care 2021; 35: 559-572
• 51 Slavoaca D, Muresanu D, Birle C. et al. Biomarkers in traumatic brain injury: new concepts. Neurol Sci 2020; 41: 2033-2044
• 52 Robinson LR, Micklesen PJ, Tirschwell DL. et al. Predictive value of somatosensory evoked potentials for awakening from coma. Crit Care Med 2003; 31: 960-967
• 53 Rothstein TL. SSEP retains its value as predictor of poor outcome following cardiac arrest in the era of therapeutic hypothermia. Crit Care 2019; 23: 327
• 54 Zafonte RD. Traumatic brain injury: an enduring challenge. Lancet Neurol 2017; 16: 766-768
• 55 Dams-O’Connor K, Juengst SB, Bogner J. et al. Traumatic brain injury as a chronic disease: insights from the United States Traumatic Brain Injury Model Systems Research Program. Lancet Neurol 2023; 22: 517-528
• 56 Pischiutta F, Caruso E, Lugo A. et al. Systematic review and meta-analysis of preclinical studies testing mesenchymal stromal cells for traumatic brain injury. NPJ Regen Med 2021; 6: 71
• 57 Latchoumane CV, Betancur MI, Simchick GA. et al. Engineered glycomaterial implants orchestrate large-scale functional repair of brain tissue chronically after severe traumatic brain injury. Sci Adv 2021; 7: eabe0207
• 58 Lin CC, Chen HY, Tseng CY. et al. Effect of Acupuncture on Recovery of Consciousness in Patients with Acute Traumatic Brain Injury: A Multi-Institutional Cohort Study. Healthcare (Basel) 2023; 11: 2267